ATE449091T1 - Substituierte triazolderivate als oxytocinantagonisten - Google Patents

Substituierte triazolderivate als oxytocinantagonisten

Info

Publication number
ATE449091T1
ATE449091T1 AT06710261T AT06710261T ATE449091T1 AT E449091 T1 ATE449091 T1 AT E449091T1 AT 06710261 T AT06710261 T AT 06710261T AT 06710261 T AT06710261 T AT 06710261T AT E449091 T1 ATE449091 T1 AT E449091T1
Authority
AT
Austria
Prior art keywords
triazole derivatives
substituted triazole
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
AT06710261T
Other languages
English (en)
Inventor
Alan Daniel Brown
Andrew A Calabrese
David Ellis
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE449091T1 publication Critical patent/ATE449091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06710261T 2005-01-20 2006-01-11 Substituierte triazolderivate als oxytocinantagonisten ATE449091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals
PCT/IB2006/000118 WO2006077496A1 (en) 2005-01-20 2006-01-11 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
ATE449091T1 true ATE449091T1 (de) 2009-12-15

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06710261T ATE449091T1 (de) 2005-01-20 2006-01-11 Substituierte triazolderivate als oxytocinantagonisten

Country Status (31)

Country Link
US (5) US7557131B2 (de)
EP (1) EP1841758B1 (de)
JP (1) JP4124805B1 (de)
KR (1) KR100936854B1 (de)
CN (1) CN101107243B (de)
AP (1) AP2007004047A0 (de)
AR (1) AR055303A1 (de)
AT (1) ATE449091T1 (de)
AU (1) AU2006207300B2 (de)
BR (1) BRPI0606463A2 (de)
CA (1) CA2595569C (de)
CR (1) CR9219A (de)
DE (1) DE602006010508D1 (de)
DK (1) DK1841758T3 (de)
DO (1) DOP2006000014A (de)
EA (1) EA200701328A1 (de)
ES (1) ES2334517T3 (de)
GB (1) GB0501190D0 (de)
GT (1) GT200600024A (de)
IL (1) IL184148A (de)
MA (1) MA29160B1 (de)
MX (1) MX2007008757A (de)
NL (1) NL1030961C2 (de)
NO (1) NO338420B1 (de)
PA (1) PA8660401A1 (de)
PE (1) PE20060875A1 (de)
TN (1) TNSN07275A1 (de)
TW (1) TW200637847A (de)
UY (1) UY29339A1 (de)
WO (1) WO2006077496A1 (de)
ZA (1) ZA200705718B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
WO2006130986A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
JP2009539884A (ja) * 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアゼチジン誘導体
US7754745B2 (en) * 2006-06-13 2010-07-13 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2010527915A (ja) * 2007-04-26 2010-08-19 アバロン ファーマシューティカルズ，インコーポレイテッド 多重環化合物及びその用途
BRPI0906727A2 (pt) * 2008-01-31 2015-08-04 Sanofi Aventis Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos
CA2712854C (en) 2008-01-31 2016-02-23 Sanofi-Aventis Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals
KR102145272B1 (ko) * 2012-07-16 2020-08-18 피브로겐, 인크. 이소퀴놀린 화합물의 제조 방법
WO2016014975A2 (en) * 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10875829B1 (en) 2016-11-18 2020-12-29 Integrative Research Laboratories Sweden Ab Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
BR112019011758A2 (pt) * 2016-12-21 2019-10-29 Jiangsu Hengrui Medicine Co derivado de azaciclobutil triazol de grupo de anel condensado, método de preparação do mesmo e uso do mesmo em medicina
TW201823231A (zh) * 2016-12-28 2018-07-01 大陸商江蘇恆瑞醫藥股份有限公司 氮雜雙環基取代的三唑類衍生物、其製備方法及其在醫藥上的應用
WO2019242642A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
CN111094273B (zh) * 2018-06-20 2022-04-12 江苏恒瑞医药股份有限公司 催产素受体抑制剂的晶型及其制备方法
TWI711612B (zh) * 2018-06-27 2020-12-01 大陸商江蘇恒瑞醫藥股份有限公司 氮雜雙環基取代的三唑類衍生物的可藥用鹽、晶型及製備方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1997036585A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249665A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891334A1 (de) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitoren von farnesylprotein-transferase
EP1003374A4 (de) 1996-12-30 2000-05-31 Merck & Co Inc Inhibitoren von farnesyl-protein-transferase
HRP20000407A2 (en) 1997-12-16 2000-10-31 Pfizer Prod Inc Combination effective for the treatment of impotence
MXPA01013452A (es) 1999-07-23 2002-07-02 Shionogi & Co Inhibodores de diferenciacion th2.
ATE250039T1 (de) 1999-10-15 2003-10-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
CA2389280C (en) 1999-11-15 2009-01-27 Janssen Pharmaceutica N.V. Triazoles as farnesyl transferase inhibitors
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
JP3873746B2 (ja) * 2000-05-19 2007-01-24 アステラス製薬株式会社 トリアゾール誘導体
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
EP1432687A2 (de) 2001-10-03 2004-06-30 Pharmacia Corporation Substitutierte fünfgliedrige polyzyclischen vebindungen für die selektive hemmung der koagulationskaskade
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
EP1673355A1 (de) * 2003-09-22 2006-06-28 Pfizer Limited Substituierte triazolderivate als oxytocinantagonisten
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
CN101107243A (zh) 2008-01-16
NL1030961C2 (nl) 2007-01-12
CR9219A (es) 2007-07-24
EP1841758B1 (de) 2009-11-18
IL184148A (en) 2013-06-27
AU2006207300A1 (en) 2006-07-27
PA8660401A1 (es) 2006-09-08
NL1030961A1 (nl) 2006-07-21
WO2006077496A1 (en) 2006-07-27
US20090253674A1 (en) 2009-10-08
US7557131B2 (en) 2009-07-07
US20060160786A1 (en) 2006-07-20
HK1113927A1 (en) 2008-10-17
US20150322042A1 (en) 2015-11-12
US20130137671A1 (en) 2013-05-30
EA200701328A1 (ru) 2007-12-28
GT200600024A (es) 2006-08-23
US9394278B2 (en) 2016-07-19
NO20074177L (no) 2007-10-16
DE602006010508D1 (de) 2009-12-31
KR20070091023A (ko) 2007-09-06
US8207198B2 (en) 2012-06-26
NO338420B1 (no) 2016-08-15
IL184148A0 (en) 2007-10-31
DK1841758T3 (da) 2010-01-18
PE20060875A1 (es) 2006-09-04
JP2008528476A (ja) 2008-07-31
AU2006207300B2 (en) 2011-03-03
ES2334517T3 (es) 2010-03-11
AR055303A1 (es) 2007-08-15
AP2007004047A0 (en) 2007-06-30
CA2595569A1 (en) 2006-07-27
UY29339A1 (es) 2006-08-31
TNSN07275A1 (fr) 2008-12-31
CN101107243B (zh) 2010-11-24
BRPI0606463A2 (pt) 2009-06-30
KR100936854B1 (ko) 2010-01-14
US9023872B2 (en) 2015-05-05
MX2007008757A (es) 2008-03-10
US10150752B2 (en) 2018-12-11
GB0501190D0 (en) 2005-03-02
ZA200705718B (en) 2008-08-27
US20170114040A1 (en) 2017-04-27
JP4124805B1 (ja) 2008-07-23
MA29160B1 (fr) 2008-01-02
DOP2006000014A (es) 2006-07-31
CA2595569C (en) 2010-07-20
EP1841758A1 (de) 2007-10-10
TW200637847A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten
ATE511502T1 (de) Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
DK1919907T5 (da) Heterocyklisk forbindelse
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
ATE490254T1 (de) Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer
DK1912503T3 (da) Fungicide blandinger indeholdende substituerede 1-methyl-pyrazol-4-ylcarboxylsyreanilider
ATE545633T1 (de) Als vasopressinantagonisten geeignete benzazepinderivate
ATE555785T1 (de) Triazolderivate als smo-antagonisten
DE602006016566D1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DK1937650T3 (da) Heterocykliske forbindelser
NL1027084A1 (nl) Gesubstitueerde triazoolderivaten als oxytocine-antagonisten.
ATE443056T1 (de) Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
ATE526324T1 (de) Substituierte imidazolverbindungen als ksp- inhibitoren
DE502006001027D1 (de) Cyanuraten
DK1870409T3 (da) Benzimidazolforbindelser
DE502006005182D1 (de) Heterocyclylamid-substituierte imidazole
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
ATE435865T1 (de) Als pde5-inhibitoren verwendete pyrazoloä4,3- düpyrimidin-5-ylderivate
DE602006007832D1 (de) Benzotriazolderivate als cannabinoidrezeptorantagonisten
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
ATE553108T1 (de) Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties